FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs
Summary
The FDA required pharmaceutical companies to warn patients and health care providers about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) linked to GLP-1 drugs used for weight loss and diabetes. NAION, sometimes called an “eye stroke,” is a rare, serious eye condition.Key Facts
- The FDA announced the warning requirement on Monday.
- The requirement applies to pharmaceutical companies that make GLP-1 drugs.
- The warnings must address a potential increased risk of NAION.
- NAION is also known as an “eye stroke.”
- The article describes NAION as rare and serious.
- The drugs covered are used for weight loss and diabetes.
- The warnings are intended for both patients and health care providers.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
